Memantine-containing transdermally absorbable liquid
AssigneeMedrx Co., Ltd.
InventorKeiko Yamasaki
Life of this patent
Estimating the term…
Abstract
An external preparation containing memantine which has less skin irritation and excellent skin permeability, and also, which is suitable for continuous administration for a long period of time. The external preparation contains memantine or a salt thereof, and further contains 0.05 to 1.5% by weight of phosphatidylcholine, 35 to 55% by weight of propylene glycol, 18 to 30% by weight of glycerine, and 22 to 32% by weight of water. The content of water less than 22% by weight may increase skin irritation, and the content of water more than 32% by weight may decrease skin permeability. The content of glycerin less than 18% by weight may increase skin irritation, and the content of glycerin more than 30% by weight may decrease skin permeability.
Claims20
A transdermal absorptive liquid formulation, comprising memantine or a salt thereof, and further comprising:
- (a) 0.05 to 1.5% by weight of phosphatidylcholine,
- (b) 35 to 55% by weight of propylene glycol,
- (c) 18 to 30% by weight glycerin, and
- (d) 22 to 32% weight of water,
- wherein the only active ingredient included in the transdermal absorptive liquid formulation is memantine or a salt thereof.
A method of treating dementia of Alzheimer's type in a subject, the method comprising administering to the subject a therapeutically effective amount of a transdermal absorptive liquid formulation comprising memantine or a salt thereof, and further comprising:
- (a) 0.05 to 1.5% by weight of phosphatidylcholine,
- (b) 35 to 55% by weight of propylene glycol,
- (c) 18 to 30% by weight glycerin, and
- (d) 22 to 32% weight of water.
Dependencies are inferred from the claim text.